Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCRX is a good fit for your portfolio.
News
-
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
-
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
-
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
-
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
-
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
-
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
-
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
Trading Information
- Previous Close Price
- $30.83
- Day Range
- $30.96–31.63
- 52-Week Range
- $25.37–42.89
- Bid/Ask
- $30.86 / $31.27
- Market Cap
- $1.46 Bil
- Volume/Avg
- 1.2 Mil / 620,773
Key Statistics
- Price/Earnings (Normalized)
- 10.24
- Price/Sales
- 2.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 712
- Website
- https://www.pacira.com
Comparables
Valuation
Metric
|
PCRX
|
VSBC
|
FTRE
|
---|---|---|---|
Price/Earnings (Normalized) | 10.24 | 3,629.76 | 31.00 |
Price/Book Value | 1.61 | 1,908.62 | 1.57 |
Price/Sales | 2.42 | 664.53 | 0.83 |
Price/Cash Flow | 7.99 | 2,904.34 | 76.51 |
Price/Earnings
PCRX
VSBC
FTRE
Financial Strength
Metric
|
PCRX
|
VSBC
|
FTRE
|
---|---|---|---|
Quick Ratio | 4.58 | 4.32 | 1.52 |
Current Ratio | 5.81 | 4.33 | 1.62 |
Interest Coverage | 8.94 | — | 1.02 |
Quick Ratio
PCRX
VSBC
FTRE
Profitability
Metric
|
PCRX
|
VSBC
|
FTRE
|
---|---|---|---|
Return on Assets (Normalized) | 6.26% | 42.38% | 2.88% |
Return on Equity (Normalized) | 11.65% | 65.38% | 6.02% |
Return on Invested Capital (Normalized) | 6.72% | 55.23% | 5.25% |
Return on Assets
PCRX
VSBC
FTRE
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Fcmlynkt | Ncdlj | $77.1 Bil | |
MKKGY
| Merck KGaA ADR | Ffcgtpkmb | Bwmxsrc | $74.3 Bil | |
HLN
| Haleon PLC ADR | Hzzbcgcw | Vyrv | $37.6 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Kbvgxnzgb | Jsgr | $18.3 Bil | |
VTRS
| Viatris Inc | Rtjlcdlrd | Nsc | $13.5 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Bzvlwcsn | Bbwd | $11.7 Bil | |
CTLT
| Catalent Inc | Jswjrsnz | Wszysc | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Skzhllhky | Ylpd | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Hytlwwyz | Syqr | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Xtdxcdbvx | Qncyjp | $3.5 Bil |